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disease. We found that NPC1−/− cells show decreased expression of APP at the cell surface and increased
processing of APP through the β-secretase pathway resulting in increased C99, sAPPβ and intracellular
Aβ40 levels. This effect is dependent on increased cholesterol levels, since cholesterol depletion reversed
cell surface APP expression and lowered Aβ/C99 levels in NPC1−/− cells to the levels observed in wt cells.
Finding that overexpression of C99, a direct γ-secretase substrate, does not lead to increased intracellular
Aβ levels in NPC1−/− cells vs. CHOwt suggests that the effect on intracellular Aβ upon cholesterol
accumulation in NPC1−/− cells is not due to increased APP cleavage by γ-secretase. Our results indicate
that cholesterol may modulate APP processing indirectly by modulating APP expression at the cell surface
and thus its cleavage by β-secretase.-intracellular domain; APP, β-
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Altered processing of the β-amyloid precursor protein (APP)
leading to increased formation of amyloid-β (Aβ) peptide is
considered to be a central event in the pathogenesis of Alzheimer's
disease (AD) [7]. Aβ is generated from the proteolytic processing of
APP by the sequential action of β- and γ-secretases. APP cleavage by
α- and β-secretase generates soluble sAPPα and sAPPβ fragments and
membrane-bound C-terminal fragments C83 (CTFα) and C99 (CTFβ),
respectively. C83 and C99 are both substrates of γ-secretase. While γ-
secretase cleavage of C99 generates Aβ peptides, γ-secretase cleavage
of C83 liberates a non-amyloidogenic species, p3. In addition, γ-
secretase cleavage of C83 and C99 liberates a C-terminal product APP-
intracellular domain (AICD) [25]. Although it has been previously
shown that within the transmembrane domain (TM) of APP the site of
γ-secretase cleavage generating Aβ/p3 is distinct from the site of γ-
cleavage generating AICD (γ40/42 and ε-site, respectively) [25], themechanism of dual γ-secretase action is still controversial [31]. While
β-secretase cleavage of APP is thought to happen primarily within
endosomal or secretory compartments [6,24,32], cleavage of APP by
α-secretase has been suggested to occur mainly at the cell surface
[29].
There is growing evidence that cholesterol contributes to the
pathogenesis of Alzheimer's disease. Elevated dietary cholesterol
uptake increased amyloid plaque formation in rabbits and transgenic
mice [23,30], and cholesterol loading and depletion affects Aβ
generation in cultured cells [5,28]. In addition to the indirect effects
of cholesterol on APP processing, recent ﬁndings suggest that
cholesterol may directly modulate the activity of β-secretase
(BACE1) [11], while contradictory results have been reported for the
effect of cholesterol on γ-secretase cleavage of APP [34,35].
The link between cholesterol and Aβ has recently been revealed in
Niemann–Pick type C (NPC) disease as well as AD. NPC is an inherited
lysosomal storage disorder caused by recessive loss of function
mutations within the NPC1/2 gene. The mutant NPC1/2 proteins fail
to transport cholesterol to the plasma membrane and endoplasmic
reticulum (ER) resulting in cholesterol accumulation in late endoso-
mal/lysosomal compartments [18]. Recent in vitro and in vivo ﬁndings
indicate that loss of NPC1 leads to a signiﬁcant increase in C99 and
intracellular Aβ production [2,10,38]. With additional reports now
linking changes in lipid homeostasis to altered APP processing and Aβ
generation, NPC pathobiology has become an important model to
study the link between cholesterol and APP processing.
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cholesterol-effect on Aβ in NPC1−/− model cells. Our data show that
cholesterol accumulation upon loss of NPC1 function affects APP
processing by altering expression of APP at the cell surface and by
favouring APP cleavage through the β-secretase pathway. These
ﬁndings add to the role of cholesterol on Aβ production and support a
link between cholesterol, AD and NPC disease.
2. Materials and methods
2.1. Antibodies
The following primary antibodies were used: 5313 (polyclonal N-
terminal APP), 6687 (polyclonal C-terminal APP, kindly provided by
Dr. H. Steiner and Dr. C. Haass), W02 (kindly provided by Dr. Konrad
Beyreuther), 9E10 (monoclonal anti-c-myc, Sigma-Aldrich) and
22C11 (monoclonal N-terminal APP, Chemicon International). Anti-
bodies 192wt and 192sw speciﬁc for the C-terminus of sAPPβ were a
generous gift from Dr. Dale Schenk.
2.2. Cell lines, cDNA constructs and transfection
Chinese hamster ovary wild-type cells (CHOwt), CHO NPC1-null
cells (NPC1−/−) and CFP-NPC1wt-stably transfected NPC1-null CHO
cells (all kindly provided by Dr. Daniel Ory) were maintained in
DMEM:F12 medium (1:1) containing 0.5 mM Na-pyruvate supple-
mented with 10% FBS, 2mM L-glutamine and antibiotic/antimycotic
(all from Sigma-Aldrich).
For transient expression, cells were transfected using GeneJuice
(Novagen, Merck) or Lipofectamine 2000 (Invitrogen) according to
the supplier's instructions. C99 and APPsw 6myc-tagged constructs
were generated using pCS2+6MT vector [8]. Twenty-four hours after
transfection, medium was removed, fresh medium was added and
further incubated for 24 h. To monitor transfection efﬁciency between
the cell lines, the cells were transiently transfected with a secreted
alkaline phosphatase (SEAP) construct (kindly provided by Drs. Stefan
Lichtenthaler and Raphael Kopan) in parallel wells/dishes. Forty-
eight hours after transfection, alkaline phosphatase activity was
measured in the medium as described previously [16] and corrected
for the protein concentration in the cell lysate.
2.3. Cholesterol depletion
The cells were plated in a 10-cm dish in 10% FBS DMEM/F12
medium. The next day, medium was removed and cells were washed
in PBS to remove the remaining FBS. Fresh medium containing 10%
lipid-deﬁcient serum (LPDS, Cocalico Biologicals Inc.) instead of 10%
FBS was added [21] and then the cells were transiently transfected.
Twenty-four hours after transient transfection, the media were
replaced with fresh 10% LPDS medium (5 ml/plate) for cholesterol
depletion and further incubated for 24 h. The media and cell lysates
were then collected (as described in the Sample preparation and
immunoblotting section) and used for biochemical assays.
2.4. Sample preparation and immunoblotting
The medium was collected, 1 mM AEBSF (Roche Applied Science)
was added and centrifuged at 4 °C for 10 min at 16000×g. The
supernatant was used for analysis of secreted Aβ40 (see ELISA Aβ
assay). For detection of secreted APP (sAPP) by western blot, aliquots
of conditioned medium normalized according to protein concentra-
tion in the cell lysate and SEAP activity were directly loaded onto an
electrophoresis gel.
Cells were washed with PBS and lysed in RIPA buffer (0.5% Na-
deoxycholate, 0.1% SDS, 1% NP40, 5 mM EDTA, 150 mM NaCl, 50 mM
Tris–HCl pH 8.0) containing a protease inhibitor cocktail (RocheApplied Science) on ice for 10 min and centrifuged at 4 °C for 10 min
at 16000×g. Supernatants were mixed with 6× sample buffer (60%
glycerol, 12% SDS, 3% DTT, 1/8 v/v 0.5 M Tris pH 6.8, bromphenol
blue) and heated at 70 °C for 10 min.
Equivalent amounts of protein, stratiﬁed according to SEAP activity,
were loaded onto SDS–PAGE gels. Immunoblot detection was carried
out using the indicated antibodies. Proteins were visualized using
chemiluminescence.
For endogenous APP–CTF analysis, cells were plated in 10-cm dish
in 10% FBS DMEM/F12 medium. Cells were treated with 1 µM DAPT
(Sigma-Aldrich) for 24 h for γ-secretase inhibition. For cholesterol
depletion, cells were grown for 48 h in 10% LPDS DMEM/F12medium.
Cells were lysed in CoIP lysis buffer (50 mM Tris pH 7.6, 150 mMNaCl,
2 mM EDTA, 1% NP40) containing protease inhibitor cocktail (Roche
Applied Science). Cell lysates were normalized according to protein
concentration and incubated with 6687 antibody and Protein A-
Sepharose (Sigma-Aldrich) at 4 °C overnight with constant rocking.
Samples were heated at 70 °C for 10 min in 2× sample buffer and
subjected to SDS–PAGE on Tris–Tricine gels [26].
2.5. ELISA Aβ assay
The levels of secreted and intracellular Aβ40 were determined by
ELISA Aβ40 kit (Invitrogen) as previously described [8]. The
colorimetric detection system was used. Aβ concentration is
expressed per mg of protein and is stratiﬁed according to SEAP
activity.
2.6. In vitro γ-secretase assay
Cells were transiently transfected with the C99-6myc construct
and 48 h after transfection total cellular membranes were isolated
[36]. In vitro γ-secretase assays were performed as previously
described [8]. To inhibit γ-secretase activity, we used γ-secretase
inhibitor WPE-III-31C (10 μM, Calbiochem). The reactions were
stopped by chilling on ice. After centrifugation (10 min at 16000×g
and 4 °C) supernatants were analyzed for Aβ40 levels using the ELISA
assay and for AICD levels by immunoblotting.
2.7. α-, β- and γ-secretase activity assay
A FRET-based assay was used to measure α-, β- and γ-secretase
activities (R&D Systems Inc.). All procedures were performed as
described in the manufacturer's protocol, except for γ-secretase.
The end-point α- and β-secretase activity was determined after
2 h of reaction at 37 °C. The ﬂuorescence was read in a ﬂuorescent
microplate reader (Fluoroskan Ascent FL, Thermo Electron Corpora-
tion) at 355 nm (excitation) and 538 nm (emission).
To measure γ-secretase activity, the postnuclear supernatant (PNS)
and total cellular membranes were collected as previously described [8].
Membranes (pellet), stratiﬁed according the protein levels, were
resuspended in Tris–CHAPSO assay buffer (50 mM Tris, pH 6.5, 2 mM
EDTAand 0.25% CHAPSO) [40]. Aliquotswere incubatedwithﬂuorogenic
γ-secretase substrate (R&D Systems Inc.) containing either none or
10 μM γ-secretase inhibitor WPE-III-31C (Calbiochem). After 2 h of
reaction at 37 °C, samples were cleared by centrifugation at 16000×g for
15 min at 4 °C. Supernatants were transferred into 96-well plate and the
ﬂuorescence was read in a ﬂuorescent microplate reader (Fluoroskan
Ascent FL, Thermo Electron Corporation, excitation/emission at 355/
538 nm). Speciﬁc γ-secretase activity is determined after subtracting the
ﬂuorescence obtained in the presence of WPE-III-31C (10 μM).
2.8. Cell surface biotinylation
Cell surface biotinylation was performed using EZ-Link™ Sulfo-
NHS-SS-Biotin (1 mg/ml) and Neutravidin™ Protein beads (all from
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reagents and cell cultures were kept on ice. The cells were washed
three times in PBS pH 8.5 (measured at 4 °C), then incubated in 1 mg/
ml EZ-Link™ Sulfo-NHS-SS-Biotin solution (Pierce) in PBS pH 8.5 for
30 min and washed twice with 100 mM glicine in PBS on plates. The
cells were then lysed in lysis buffer (1% NP40, 0.1% SDS in PBS pH 8.5)
in the presence of a protease inhibitor cocktail (Roche Applied
Science, Germany). Lysates were incubated for 20 min on ice,
centrifuged at 4 °C for 10 min at 16000×g. Supernatants (normalized
per mg of protein) were incubated overnight with 50 μl of
Neutravidin™ Protein beads (Pierce) with constant rocking. Neutra-
vidin beads were washed three times with PBS then dried by
aspiration, resuspended in 2× sample buffer, heated for 10 min at
70 °C and used for Western blot analysis of the cell surface APP. For
detection of the total APP levels, the cell lysates were blotted and
analyzed as indicated. The signals were quantiﬁed and expressed as
the ratio of the cell surface and total (mature + immature) APP levels.
2.9. Cholesterol levels
The levels of total cholesterol were determined in cell lysates using
the Amplex Red Cholesterol Assay kit (Molecular Probes, Invitrogen).
The ﬂuorescence was read in a ﬂuorescent microplate reader
(Fluoroskan Ascent FL, Thermo Electron Corporation) at 530 nm
(excitation) and 590 nm (emission).
2.10. Filipin staining and immunocytochemistry
The cells were grown on coverslips. Filipin staining was done as
described [17]. The cells were mounted (Polyvinyl alcohol mounting
medium with DABCO antifading, Fluka) and were viewed by
ﬂuorescence microscopy (Olympus BX51).
Non-permeabilized cells were stained with 5313 antibody (N-
terminal APP) for 10 min on ice to detect cell surface APP. Cells were
then ﬁxed in 4% paraformaldehyde (Sigma-Aldrich) for 15 min and
were further incubated for 1 h with secondary anti-rabbit-Alexa488
antibody (Molecular Probes, Invitrogen). For detection of intracellular
APP, cells were ﬁxed, permeabilized with 0.2% saponin (Sigma-
Aldrich) and immunostained with antibody 6687 (C-terminal APP)
overnight following 1 h of incubation with secondary anti-rabbit-
Alexa488 antibody (Molecular Probes, Invitrogen). The cells were
mounted (Polyvinyl alcohol mounting medium with DABCO antifad-
ing, Fluka) and were viewed by Leica inverted ﬂuorescent confocal
microscope.
3. Results
3.1. sAPPβ and CTFβ/C99 are increased in NPC1−/− cells
It has been previously reported that accumulation of cholesterol in
late endosomal/lysosomal compartments as a result of NPC1 dysfunc-
tion causes increased C99/CTFβ and Aβ formation [2,10,38]. Since C99
and Aβ generation require β-secretase cleavage, we investigated
whether this pathway may be favoured by cholesterol accumulation
in NPC1−/− cells. To test this, we compared APP processing in CHO
NPC1-null cells (NPC1−/− cells) and parental CHOwt cells. By analyzing
endogenous levels of cholesterol and endogenous C-terminal APP
fragments (CTFs), we show that NPC1−/− cells behave as previously
observed U18666A-treated cells or NPC1-mutant cell lines/mouse
model [2,10,38]: they exhibit ∼2-fold higher total cholesterol levels
than CHOwt cells (Fig. 1A, pb0.01), show accumulation of cholesterol in
punctuate endocytic structures (Fig. 1B) and show substantially
increased levels of endogenous APP C-terminal fragments (CTFs)
(Fig. 1C). The origin of these APP–CTF fragments was conﬁrmed by
their accumulation after DAPT treatment (Fig. 1D). Using NPC1 stably
transfected NPC1−/− cells, we conﬁrmed that this phenotype wasdependent upon NPC1 function and was not a secondary effect of NPC1
deletion because in NPC1 expressing NPC1−/− cells, cholesterol levels/
accumulation as well as the levels of APP–CTFs were reversed to the
levels seen in wt cells (Fig. 1A, B and C).
Surprisingly, analysis of endogenous levels of total sAPP in
conditioned media showed no difference between wt and NPC1−/−
cells. However, further analysis of sAPPβ species revealed its marked
increase in NPC1−/− cells vs. CHOwt (Fig. 1E), suggesting that the loss
of NPC1 increases β-secretase cleavage of APP. We could not
speciﬁcally analyze the sAPPα secreted from the CHO cell lines
because antibodies to human Aβ1-16 do not detect hamster APP
sequence (GenBank accession number AF030413), which is the same
as the sequence in other rodents. For this reason, we only analyzed
endogenous levels of total sAPP and sAPPβ by immunoblotting with
antibodies 22C11 and 192wt, respectively, which recognize both
human and rodent sAPP.
To investigate APP processing between wt and NPC1−/− cells in
more detail and in order to be able to speciﬁcally detect the α-
secretase cleavage products of APP, the cells were transiently
transfected with the APPsw-6myc construct [8]. We observed that
C99 levels were signiﬁcantly increased in NPC1−/− vs. CHOwt cells
(Fig. 2A, pb0.05), while levels of C83 were not signiﬁcantly altered
(Fig. 2A). To further analyze α- and β-secretase cleavage of APP in
NPC1−/− cells, we measured secreted APP levels (sAPPβ, sAPPα and
sAPPtotal) in the media of APP-transfected cells. In accord with our
previous results on endogenous levels (Fig. 1E), we detected a
signiﬁcant increase in sAPPβ (Fig. 2B, pb0.05) levels and, additionally,
a decrease in sAPPα levels (Fig. 2B, pb0.01) in NPC1−/− vs. CHOwt
cells. These results suggest that cholesterol accumulation upon loss of
NPC1 may favour APP processing through the β-secretase pathway
and lower cleavage by α-secretase.
3.2. NPC1 loss causes increase of intracellular form of Aβ but does not
cause an increase of AICD
The levels of intracellular and secreted Aβwere analyzed using an
ELISA assay (Biosource Int. Inc., Invitrogen) in APPsw-6myc transiently
transfected cells. We detected increased levels of soluble (RIPA-
extractable) and insoluble (formic acid (FA)-extractable) intracellular
Aβ40 inNPC1−/− cells compared to CHOwt cells (Fig. 2C, left and right
panel, respectively), while secreted Aβ40 levels were not changed
(Fig. 2D). In agreement with Yamazaki et al. [38] and Jin et al.[10], the
levels of aggregated FA-extractable form of intracellular Aβ40 were
signiﬁcantly increased (by ∼10-fold, pb0.01) in NPC1−/− cells
compared to a slight increase in the soluble RIPA-extractable form
(∼2-fold, pb0.05) with no increase in secreted Aβ40, indicating that
accumulation of cholesterol upon loss of NPC1 mainly affects the
intracellular pool of Aβ and not secreted Aβ. In addition, we conﬁrmed
that this increase in intracellular Aβ in NPC1−/− cells was directly
dependent on NPC1 function, as we observed for cholesterol and APP–
CTF levels (Fig. 1), since expression of NPC1 in NPC1−/− cells reverted
Aβ levels to those seen in wt cells (Fig. 2C). Intracellular Aβ42 levels
were below the detection limit of the ELISA assay used (Biosource Int.
Inc., Invitrogen) and thus are not shown. Using APPwt-6myc construct,
we observed the same effect of intracellular Aβ40 increase upon NPC1
loss (not shown); however, the extent of Aβ40 accumulation using
APPsw construct was far more substantial resulting in more reliable
read-outs by ELISA assay.
Since γ-secretase cleavage of APP generates two products: Aβ,
generated by γ-cleavage at the γ-site and AICD, generated by γ-
cleavage at the ε-site, we investigated whether accumulation of
cholesterol in NPC1-deﬁcient cells would cause an increase in AICD
levels in parallel with an increase in intracellular Aβ. In contrast to
intracellular Aβ levels (Fig. 2C), we did not detect increased AICD
levels in APPsw-6myc transfected NPC1−/− cells vs. CHOwt (Fig. 2A).
This result indicates that the loss of NPC1 affects Aβ generation by
Fig. 1. NPC1−/− cells show increased levels of total cholesterol, accumulation of free cholesterol and increased levels of endogenous C-terminal APP-stubs (CTFs) and sAPPβ. Total
cholesterol levels, free cholesterol accumulation and endogenous levels of APP–CTFs and sAPPβwere analyzed between CHOwt, NPC1−/− cells and NPC1-transfected NPC1−/− cells.
(A) Total cholesterol levels were determined in cell lysates by AmplexRed cholesterol assay (Molecular probes, Invitrogen). Shown are mean and SEM of three independent
experiments. Statistical analysis was performed using Student's t-test: **pb0.01, ***pb0,001. (B) Filipin staining (Sigma-Aldrich) shows punctuate accumulation of free cholesterol
in NPC1−/− cells compared to CHOwt cells and NPC1-transfected NPC1−/− cells. (C) The levels of APP–CTF stubs (CTFs) were determined in cell lysates by immunoprecipitation and
western blotting as indicated. (D) Treatment with a γ-secretase inhibitor DAPT (1 μM) conﬁrmed that the CTF stubs analyzed were indeed γ-secretase substrates since they
accumulated upon DAPT treatment. (E) The levels of sAPPtotal and sAPPβ were determined in the media by western blotting as indicated.
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cleavage.
3.3. Increased Aβ levels in NPC1−/− cells are not due to increased
C99-cleavage by γ-secretase
To directly assess γ-secretase cleavage of APP in NPC1−/− cells,
without the confounding effects of NPC1 loss on α-/β-secretase
processing of APP, we overexpressed a C99 construct in NPC1−/− cells
and compared its processing to that in CHOwt cells. Interestingly, we
found that the levels of soluble (RIPA-extractable) and insoluble (FA-
extractable) Aβ40 were similar in C99-transfected CHOwt and NPC1−/−
cells (Fig. 3A, left and right panel, respectively). This result suggests that
the effect on intracellular Aβ upon cholesterol accumulation inNPC1−/−
cells is not due to increased APP cleavage by γ-secretase. Since an
increase in intracellular Aβ was observed in APP- (Fig. 2C) but not C99-
transfected (Fig. 3A) NPC1−/− vs. CHOwt cells, this result provides
further support for the hypothesis that increased Aβ in NPC1−/− cells is
due to favoured APP processing by β-secretase, which is in agreement
with the increased sAPPβ levels. In addition, we observed similar levels
of AICD between C99-transfected CHOwt and NPC1−/− cells (Fig. 3B),
further conﬁrming that γ-secretase dependent formation of AICD is not
altered in NPC1−/− cells (Fig. 2A).
3.4. Activities of α-, β- and γ-secretase are not altered in NPC1−/− cells
To investigatewhether altered C99 and sAPPα/β levels inNPC1−/−
cells are due to altered activities of α- and/or β-secretase, we
performed a FRET-based assay (R&D Systems Inc.). Since these
fragments are direct products of APP cleavage by α- and β-secretase,we hypothesized that cholesterol accumulation in NPC1−/− cells may
alter APP processing by modulating the activities of α- and/or β-
secretase. However, we observed that the kinetics (not shown) and
the end-point activities of both α- and β-secretases were similar in
CHOwt and NPC1−/− cells (Fig. 4A), indicating that the altered
processing of APP through α-/β-secretase pathways in NPC1−/− cells
is not due to altered activities of either α- or β-secretase.
To analyze γ-secretase activity in CHOwt and NPC1−/− cells, we
performed a FRET-based assay (R&D Systems Inc.) (Fig. 4A) and an in
vitro γ-assay (Fig. 4B). Total cellular membranes isolated from C99-
transfected cells showed similar rates of in vitro generation of Aβ40
(Fig. 4B, upper panel) and AICD (Fig. 4B, lower panel) in CHOwt and
NPC1−/− cells upon1 and4 h incubation at 37 °C. Treatmentwith theγ-
secretase inhibitor WPE-III-31C (10 μM) completely blocked in vitro
formation of both Aβ40 and AICD in both cell lines (Fig. 4B), conﬁrming
that the activitymeasured in vitrowas indeed γ-secretase. In addition, a
FRET-based assay showed similar levels of γ-activity between wt and
NPC1−/− cells (Fig. 4A). Together, these ﬁndings support that activity of
γ-secretase is similar between CHOwt and CHONPC1-null cells and that
increased intracellular Aβ levels in NPC1−/− cells are not due to
increased activity of γ-secretase.
3.5. Increased formation of intracellular Aβ and APP–CTFs in NPC1−/−
cells is dependent on cholesterol levels
To test whether increased intracellular Aβ/CTFs levels in NPC1−/−
cells are related to higher cholesterol levels, we reduced the levels of
cholesterol in both CHOwt andNPC1−/− cells by growing the cells in a
lipid-deﬁcient serum (LPDS) and we compared APP processing in
untreated and cholesterol-depleted cells (Fig. 5). In NPC1−/− cells
Fig. 2.NPC1−/− cells show increased APP processing through the β-secretase pathway. CHOwt, NPC1−/− cells and NPC1-transfected NPC1−/− cells were transiently transfected with
APPsw-6myc and wemonitored (A) C99, C83 and AICD levels in the cell lysate by western blotting (left panel) and quantiﬁcation of the results with Image J (right panel); (B) sAPPβ,
sAPPα and sAPP total levels by western blotting (left panel) and quantiﬁcation of the results (right panel); (C) soluble (RIPA-extractable, left panel) and insoluble (FA-extractable,
right panel) intracellular Aβ40 levels (ELISA assay, BioSource International Inc.); and (D) secreted Aβ40 levels (ELISA assay, BioSource International Inc.). Shown are mean and SEM
of three independent experiments. Statistical analysis was performed using Student's t-test: *pb0.05, **pb0.01.
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pb0.001) to levels comparable to untreated wt cells (Fig. 5A). Filipin
staining conﬁrmed a strong reduction in the accumulation of free
cholesterol in LPDS-grown NPC1−/− cells compared to cells grown in
FBS media (Fig. 5B). Cholesterol depletion lowered the levels of both
soluble (pb0.05) and insoluble (pb0.01) Aβ40 in NPC1−/− cells
(Fig. 5C, left and right panel, respectively) to levels comparable with
wt cells. The same effect was observed when we depleted cholesterol
levels using statin treatment in LPDS media (not shown). Since we
observed that cells under statin treatment were less viable compared
to the cells grown in LPDS media alone, causing the same effect oncholesterol reduction, we used LPDS-grown cells as a model of
cholesterol reduction. Lowering cholesterol levels in CHOwt cells
(Fig. 5A, pb0.001) caused a signiﬁcant decrease of insoluble (FA-
extractable) intracellular Aβ40 (pb0.01) as well (Fig. 5C, left and right
panel, respectively).
Cholesterol depletion in NPC1−/− cells also caused a strong
reduction of both endogenous and exogenous APP–CTFs levels
(Fig. 5D and E, respectively), supporting the hypothesis that increased
C-terminal APP fragment formation upon NPC1 loss is related to high
cholesterol levels/accumulation. The observation that cholesterol
depletion in NPC1−/− cells exerts the same effect on APP–CTFs and
Fig. 3. Overexpression of C99, a direct γ-secretase substrate, in NPC1−/− cells does not lead to increased Aβ levels. The CHOwt and NPC1−/− cells were transiently transfected with
C99-6myc construct. (A) In C99-transfected NPC1−/− cells, the levels of both soluble (left panel) and insoluble (right panel) intracellular Aβ40 were similar to the levels seen in wt
cells (ELISA assay, BioSource International Inc.). (B) Processing of C99-6myc revealed similar levels of AICD between CHOwt and NPC1−/− cells.
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further conﬁrms that the effect on intracellular Aβ and APP–CTFs
upon loss of NPC1 is due to the cholesterol levels/accumulation
caused by NPC1 loss rather than NPC1 function directly.Fig. 4. Activities of α-, β- and γ-secretase are not altered in NPC1−/− cells. (A) Activities
of α-, β- and γ-secretase were measured by a FRET-based assay (R&D Systems Inc.).
(B) In vitro γ-secretase assay using total cellular membranes showed similar rate of
Aβ40 (upper panel) and AICD synthesis (lower panel) in CHOwt and NPC1−/− cells.
Shown are mean and SEM of three independent experiments. Statistical analysis was
performed using Student's t-test.3.6. APP expression at the cell surface is markedly decreased in NPC1−/−
cells
To further investigate the effect of NPC1 loss on APP processing
through α- and β-secretase pathways, we analyzed the levels of
endogenous APP at the cell surface in CHOwt and NPC1−/− cells. We
hypothesized that cell surface expression of APP would be altered
upon cholesterol accumulation in NPC1−/− cells leading to altered
processing through either α- or β-secretase pathways. Indeed, the
biotinylation assay showed a signiﬁcant decrease in cell surface APP in
NPC1−/− cells compared to CHOwt (pb0.001, Fig. 6A and B). These
ﬁndings, together with our results of APP processing in CHOwt and
NPC1−/− cells (Figs. 1 and 2), further suggest that cholesterol
accumulation upon loss of NPC1 causes a shift in APP localization
which leads to increased cleavage of APP by β-secretase. We also
observed a marked difference in endogenous APP localization
between CHOwt and CHO-NPC1−/− cells using confocal microscopy
(Fig. 6C). To detect cell surface APP, we stained non-permeabilized
cells with APP ectodomain 5313 antibody. We observed a pronaunced
dotted cell membrane staining in CHOwt cells which was reduced in
NPC1−/− cells. Furthermore, the analysis of APP localization using
6687 antibody on permeabilized cells showed strong perinuclear
signal in CHOwt cells, while in NPC1−/− cells we observed a strong
vesicular staining of APP at a periphery (Fig. 6C).
Either NPC1 expression or cholesterol depletion in NPC1−/− cells
reversed the levels of endogenous APP at the cell surface (Fig. 6A and
B), supporting the hypothesis that decreased APP localization at the
cell surface due to cholesterol accumulation upon NPC1 loss may be
the primary cause of altered APP processing in NPC1−/− cells.
4. Discussion
Cholesterol levels have been implicated in the pathogenesis of
Alzheimer's disease (AD) [9,37] and a non-AD disorder with disturbed
cholesterol homeostasis, Niemann–Pick type C (NPC), parallels AD by
showing neurodegeneration, tau pathology and increased formation
of Aβ [1,2,4,10,38]. The results of this work show that increased levels
of intracellular Aβ upon loss of NPC1 function are tightly linked to
cholesterol-mediated defects in NPC1−/− cells, supporting a link
between altered cholesterol metabolism/levels and Aβ production. In
addition, we show that increased formation of intracellular Aβ upon
cholesterol accumulation in NPC1−/− cells is due to increased APP
cleavage by β-secretase most likely the result of decreased APP
expression at the cell surface.
In contrast to previous reports that used U18666A compound to
mimic NPC disease or NPC1mutant cells/mouse model, we used CHO
cells that are null for the NPC1 gene to study how the loss of NPC1
function modulates APP processing. Our results on Aβ and APP–CTF
levels conﬁrm that the NPC model we have used shows an AD-like
Fig. 5. Cholesterol depletion in NPC1−/− cells reverts intracellular Aβ/CTF levels to that seen in CHOwt cells. To deplete cholesterol, APPsw-6myc transiently transfected cells were
grown in the medium containing 10% LPDS for 48 h. We measured (A) the levels of total cholesterol by AmplexRed cholesterol assay (Molecular Probes, Invitrogen),
(B) accumulation of free cholesterol by ﬁlipin staining, (C) the levels of soluble (left panel) and insoluble Aβ40 (right panel) by ELISA assay (BioSource International Inc.), (D) the
levels of endogenous APP–CTF stubs and (E) the levels of exogenous APP–CTF stubs by western blotting. Shown are mean and SEM of three independent experiments. Statistical
analysis was performed using Student's t-test: *pb0.05, **pb0.01, ***pb0.001.
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CHONPC1−/− cells showed increased intracellular Aβ levels as well as
increased levels of APP–CTFs compared to CHOwt cells. Interestingly,
NPC1−/− in CHO cells caused a signiﬁcant increase in the insoluble
(aggregated) pool of intracellular Aβ compared to the soluble
intracellular pool with no effect on secreted Aβ levels, similar to
what was previously observed in U18666A-treated CHO cells [38] and
in U18666A-treated primary mouse cortical neurons [10]. While we
observed a strong increase in intracellular Aβ40 species (Aβ42 levels
were below the detection limit of the ELISA assay used), previous
studies showed an increase of Aβ42 only [10,38] or both Aβ40 and
Aβ42 [2]. Although these discrepancies may be due to the differentcell lines used and/or the way NPC disease was modeled, they all
show that cholesterol accumulation upon loss of NPC1 leads to
increased C99 levels and increased levels of the intracellular pool of
aggregated Aβ. Using NPC1-stably transfected CHO NPC1−/− cells, we
conﬁrmed that NPC1 expression rescued the Aβ and C99 phenotype
observed in the NPC1−/− cells.
The three main ﬁndings in this work support the hypothesis that
increased formation of intracellular Aβ upon cholesterol accumula-
tion in NPC disease is due to altered APP localization leading to
increased APP cleavage by β-secretase. First, steady-state levels of
APP–CTF/C99 and sAPPβ, the two direct products of APP cleavage by
β-secretase, were increased in NPC1−/− cells compared to CHOwt.
Fig. 6. NPC1−/− cells show decreased expression of APP at the cell surface and accumulation of APP in a punctuate vesicular structures. Endogenous levels of APP at the cell surface of
CHOwt, NPC1−/− cells and NPC1-transfected NPC1−/− cells were monitored using a biotinylation assay. A signiﬁcant decrease of cell surface APP was observed in NPC1−/− cells.
Note that both NPC1-expression (A) and cholesterol depletion (B) reversed the levels of cell surface APP to levels similar to those seen in wt cells. Blots were quantiﬁed with Image J.
Statistical analysis was performed using Student's t-test: *pb0.05, ***pb0.001. (C) Immunostaining with 5313 and 6687 antibody revealed a marked difference in APP staining
between CHOwt and NPC1−/− cells. Cell surface staining of non-permeabilizied cells with ectodomain 5313 antibody revealed stronger dotted signal at the cell surface of wt cells.
The 6687 antibody staining of permeabilizied cells showed that APP was localized more perinuclearly in wt cells, while upon NPC1 loss it accumulated in vesicular punctuate
structures at a periphery. Arrow indicates the strong cell surface staining in CHOwt cells.
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substrate and the product of β-secretase APP cleavage, showed that
increased β-secretase generation of C99 is a prerequisite for the Aβ
increase in NPC1−/− cells. The observation that intracellular Aβ levels
are not increased in C99-expressing NPC1−/− cells further indicates
that increased Aβ levels upon loss of NPC1 are not due to decreased
clearance nor are due to cholesterol-mediated accumulation of
intracellular Aβ/C99 per se. Our ﬁndings show that the effect on Aβin NPC1−/− cells is due to altered APP processing upstream of C99
cleavage by γ-secretase.
Third, biotinylation experiments showed a marked decrease in cell
surface APP in NPC1−/− cells compared to wt cells, suggesting that
altered APP processing by β-secretase in NPC1−/− cells may primarily
be caused by altered APP localization, i.e. decreased APP expression at
the cell surface. Since APP cleavage by α-secretase is thought to
mainly occur at the cell surface [29], while β-secretase cleavage is
690 M. Malnar et al. / Biochimica et Biophysica Acta 1802 (2010) 682–691suggested to happen within endosomal and secretory compartments
[6,24,32], ﬁnding less APP at the cell surface upon loss of NPC1 would
be expected to lead to decreased processing by α-secretase with a
parallel increase in β-secretase cleavage. Indeed, an increase of sAPPβ
was observed either at endogenous (APPwt) or exogenous (using
APPsw construct) levels as well as a decrease of sAPPα. To further
address β-secretase cleavage of APP in NPC1−/− cells, the goal of
future studies would be to examinewhether cholesterol accumulation
in these cells causes increased APP endocytosis and/or increased APP/
BACE1 colocalization within endosome/secretory compartments.
Indeed, in NPC1−/− cells APP staining revealed punctuate structures,
suggesting APP accumulation in a certain intracellular compartments.
Previous reports have shown that cholesterol may modulate endocy-
tosis [14]. Von Arnim et al. [33] demonstrated that cholesterol
modulates APP cleavage by β-secretase and APP/β-secretase prox-
imity within endosome compartments. These authors found that
cholesterol enrichment increases sAPPβ levels and decreases sAPPα
secretion, similar to our observation upon cholesterol accumulation in
NPC1−/− cells. In addition, we have recently shown that cholesterol
accumulation in NPC1−/− cells leads to increased APP–CTF partition-
ing within cholesterol-rich lipid rafts [13].
Our cholesterol depletion experiments in CHOwt and CHO NPC1−/−
cells showed that increased intracellular Aβ/C99 upon loss of NPC1 is
linked to cholesterol levels/accumulation. Cholesterol depletion in
NPC1−/− cells signiﬁcantly lowered C99 as well as aggregated
intracellular Aβ levels to levels similar to those observed in wt cells
and in NPC1 transfected NPC1−/− cells. Importantly, either cholesterol
depletion or NPC1-expression in NPC1−/− cells markedly increased the
levels of APP at the cell surface, further supporting the hypothesis that
cholesterol may modulate APP trafﬁcking and thus its cleavage by α-
secretase (at the cell surface) and β-secretase (within endosome/
secretory compartments). Finding that lowering cholesterol levels
corrects the AD-like phenotype in NPC1−/− cells by increasing APP
expression at the cell surface indicates that altered APP trafﬁcking may
be the primary cause of the cholesterol-effect on APP metabolism and
on the pathogenesis of Alzheimer's disease. However, since we used
LPDS-grown cells as a model for cholesterol depletion, we cannot
exclude the possibility that the observed effect on APP processing could
be due to ApoE depletion as well [39].
Although it has been suggested that cholesterol may modulate
activities of α-, β- and/or γ-secretase, we show that cholesterol
accumulation upon NPC1 deﬁciency does not alter the activities of α-,
β- and/or γ-secretase. While similar activities of α- and β-secretase
were previously detected in NPC and wt mouse, γ-secretase activity
was reported to be slightly increased in NPC mouse brain homo-
genates [2]. However, using an in vitro γ-secretase assay, we further
conﬁrmed no change in γ-activity between wt and NPC1−/− cells.
It is intriguing that increased processing of APP through the β-
secretase pathway in NPC1−/− cells generated an increase of only the
intracellular and not the secreted pool of Aβ, a ﬁnding that was
observed in this study as well as by Yamazaki et al. [38] and Jin et al.
[10]. The effect of cholesterol accumulation on intracellular Aβ could
be explained by either decreased recycling of APP to the plasma
membrane, and thus less APP secretion, and/or an impairment of the
autophagic pathway in NPC1−/− cells. Indeed, decreased recycling of
the transferrin receptor (TfR) as well as Bodipy-labeled lactosylcer-
amide (Bodipy-LacCer) inNPC1−/− cells has been previously reported
[12,20]. In addition, altered trafﬁcking within the endocytic pathway
has been observed for several other proteins including cation-
independent mannose-6-phosphate receptor (CI-MPR) [21], Rab4
[3] and TfR (Pipalia et al., 2007). However, since sAPPβ levels are
increased in NPC1−/− cells, we speculate that recycling of APP upon
NPC1 dysfunctionmay not be affected but rather that an accumulation
of autophagosomes and defective autophagosome-lysosome fusion,
previously observed in lysosomal storage disorders [27], could explain
the speciﬁc effect of NPC1-loss on intracellular Aβ and not on itssecreted pool. Although cholesterol-mediated activation of autophagy
was reported in NPC disease by increased beclin 1 expression [15,19],
Settembre et al. [27] showed inefﬁcient degradation of exogenous
aggregate-prone proteins (expanded huntingtin and mutated α-
synuclein) in lipid storage disorders multiple sulfatase deﬁciency
(MSD) and mucopolysaccahridosis type IIIA (MPSIIIA). Since macro-
autophagy, i.e. accumulation of autophagosomes and late autophagic
vacuoles (AV), has been observed early in Alzheimer's disease and is a
major reservoir of intracellular Aβ [40], we speculate that cholesterol
accumulation upon loss of NPC1 sequesters APP and β-secretase
(BACE1) within accumulated autophagosomes [41] resulting in
increased β-secretase cleavage of APP and thus increased CTFβ/C99
and intracellular Aβ generation. However, further studies are
necessary to conﬁrm this.5. Conclusions
In summary, our results demonstrate that cholesterol accumula-
tion upon NPC1 loss of function affects APP partitioning between α-
and β-secretase pathways favouring APP cleavage by β-secretase.
Furthermore, our ﬁndings suggest that altered APP cell surface
expression/localization may be a primary cause of altered APP
processing upon cholesterol accumulation in NPC1−/− cells. We
postulate that accumulation of cholesterol upon loss of NPC1 alters
APP compartmentalization causing increased cleavage by β-secretase
and increased C99 and Aβ levels. These ﬁndings add to themechanism
of the cholesterol-effect on APP metabolism and demonstrate that
there is a link between cholesterol homeostasis, APP metabolism and
the pathogenesis of Alzheimer's disease.Acknowledgements
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